Clinical Trial

A Study of DII235 in Adults With Elevated Lipoprotein(a)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
Protocol Amendment History 6 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-23
notable Enrollment increased: 200 -> 233 participants 2026-06-23
notable Trial sites reduced: 66 -> 63 locations 2026-06-23
notable Primary completion moved earlier: 2027-09-08 -> 2027-04-26 2026-06-09
minor Completion moved earlier: 2028-09-08 -> 2028-04-25 2026-06-09
notable Trial sites expanded: 60 -> 66 locations 2026-04-02
Trial Details
NCT Number NCT07235046
Lead Sponsor Novartis Pharmaceuticals
Conditions Lipoprotein Disorder
Enrollment 234 participants
Start Date 2025-12-02
Primary Completion 2027-04-26 (estimated)
Study Completion 2028-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-07